Vivos Therapeutics Inc（VVOS）资讯与事件VVOSVivos Therapeutics Inc

Vivos Therapeutics Receives Nasdaq Compliance Notice

Vivos Therapeutics announced receipt of a letter from the Listing Qualifications staff of Nasdaq on October 20 stating that the company currently complies with Listing Rule 5550(b)(1), requiring the company to maintain stockholders' equity of at least $2.5M. The company previously reported the closing of its acquisition of an 11% fully diluted equity interest in SOD Sciences and a 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test. As part of the transaction, the company issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12M, which is expected to increase stockholders' equity by more than $10M. "While the company regained compliance with the stockholders' equity requirement following the closing of the transaction with SOD, we continue executing our strategy to maintain compliance and grow our business," said Kirk Huntsman, chairman and CEO.

Vivos Therapeutics Acquires 11% Stake in SOD Sciences for $12M

Vivos Therapeutics announced that it has entered into a definitive mutual stock purchase and asset exchange agreement to acquire an 11% fully diluted equity interest in SOD Sciences and a 50% undivided co-ownership interest in SOD's proprietary pseudohypoxia early-warning test, in exchange for 12,000 shares of newly created series C convertible preferred stock with an aggregate stated value of $12M. Closing is subject to customary conditions, including auditor concurrence, consent of the holder of the company's series B non-convertible preferred stock, and Nasdaq notification, and is expected to occur on or about October 15. No cash consideration is payable under the agreement. The company believes the transaction would increase reported stockholders' equity and support the company's efforts to regain compliance with Nasdaq rules. The preferred stock is convertible into shares of common stock at a fixed conversion price of 15c per share, representing up to 80M shares in the aggregate, subject to a 19.99% exchange cap pending stockholder approval.

Vivos Therapeutics Implements Restructuring Plan, Expected to Save $3.6M Annually

Vivos Therapeutics announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6M annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in the fourth quarter of 2026. In addition to the announced expense reductions, management has also pursued a number of revenue growth initiatives that are beginning to deliver meaningful financial returns.